Literature DB >> 25320311

The human CD8+ T cell responses induced by a live attenuated tetravalent dengue vaccine are directed against highly conserved epitopes.

Daniela Weiskopf1, Michael A Angelo2, Derek J Bangs2, John Sidney2, Sinu Paul2, Bjoern Peters2, Aruna D de Silva3, Janet C Lindow4, Sean A Diehl4, Stephen Whitehead5, Anna Durbin6, Beth Kirkpatrick4, Alessandro Sette2.   

Abstract

UNLABELLED: The incidence of infection with any of the four dengue virus serotypes (DENV1 to -4) has increased dramatically in the last few decades, and the lack of a treatment or vaccine has contributed to significant morbidity and mortality worldwide. A recent comprehensive analysis of the human T cell response against wild-type DENV suggested an human lymphocyte antigen (HLA)-linked protective role for CD8(+) T cells. We have collected one-unit blood donations from study participants receiving the monovalent or tetravalent live attenuated DENV vaccine (DLAV), developed by the U.S. National Institutes of Health. Peripheral blood mononuclear cells from these donors were screened in gamma interferon enzyme-linked immunosorbent spot assays with pools of predicted, HLA-matched, class I binding peptides covering the entire DENV proteome. Here, we characterize for the first time CD8(+) T cell responses after live attenuated dengue vaccination and show that CD8(+) T cell responses in vaccinees were readily detectable and comparable to natural dengue infection. Interestingly, whereas broad responses to structural and nonstructural (NS) proteins were observed after monovalent vaccination, T cell responses following tetravalent vaccination were, dramatically, focused toward the highly conserved NS proteins. Epitopes were highly conserved in a vast variety of field isolates and able to elicit multifunctional T cell responses. Detailed knowledge of the T cell response will contribute to the identification of robust correlates of protection in natural immunity and following vaccination against DENV. IMPORTANCE: The development of effective vaccination strategies against dengue virus (DENV) infection and clinically significant disease is a task of high global public health value and significance, while also being a challenge of significant complexity. A recent efficacy trial of the most advanced dengue vaccine candidate, demonstrated only partial protection against all four DENV serotypes, despite three subsequent immunizations and detection of measurable neutralizing antibodies to each serotype in most subjects. These results challenge the hypothesis that seroconversion is the only reliable correlate of protection. Here, we show that CD8(+) T cell responses in vaccinees were readily detectable and comparable to natural dengue virus infection. Detailed knowledge of the T cell response may further contribute to the identification of robust correlates of protection in natural immunity and vaccination against DENV.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25320311      PMCID: PMC4301095          DOI: 10.1128/JVI.02129-14

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  28 in total

Review 1.  Nine major HLA class I supertypes account for the vast preponderance of HLA-A and -B polymorphism.

Authors:  A Sette; J Sidney
Journal:  Immunogenetics       Date:  1999-11       Impact factor: 2.846

2.  Research on dengue during World War II.

Authors:  A B SABIN
Journal:  Am J Trop Med Hyg       Date:  1952-01       Impact factor: 2.345

Review 3.  From research to phase III: preclinical, industrial and clinical development of the Sanofi Pasteur tetravalent dengue vaccine.

Authors:  Bruno Guy; Beatrice Barrere; Claire Malinowski; Melanie Saville; Remy Teyssou; Jean Lang
Journal:  Vaccine       Date:  2011-07-13       Impact factor: 3.641

Review 4.  The three-dimensional structure of peptide-MHC complexes.

Authors:  D R Madden
Journal:  Annu Rev Immunol       Date:  1995       Impact factor: 28.527

5.  Cross-reactive CD8+ T-cell immunity between the pandemic H1N1-2009 and H1N1-1918 influenza A viruses.

Authors:  Stephanie Gras; Lukasz Kedzierski; Sophie A Valkenburg; Karen Laurie; Yu Chih Liu; Justin T Denholm; Michael J Richards; Guus F Rimmelzwaan; Anne Kelso; Peter C Doherty; Stephen J Turner; Jamie Rossjohn; Katherine Kedzierska
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-28       Impact factor: 11.205

6.  Enhanced infection of liver sinusoidal endothelial cells in a mouse model of antibody-induced severe dengue disease.

Authors:  Raphaël M Zellweger; Tyler R Prestwood; Sujan Shresta
Journal:  Cell Host Microbe       Date:  2010-02-18       Impact factor: 21.023

7.  Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification.

Authors:  Scott J Balsitis; Katherine L Williams; Ruben Lachica; Diana Flores; Jennifer L Kyle; Erin Mehlhop; Syd Johnson; Michael S Diamond; P Robert Beatty; Eva Harris
Journal:  PLoS Pathog       Date:  2010-02-12       Impact factor: 6.823

8.  The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response.

Authors:  Rama S Akondy; Nathan D Monson; Joseph D Miller; Srilatha Edupuganti; Dirk Teuwen; Hong Wu; Farah Quyyumi; Seema Garg; John D Altman; Carlos Del Rio; Harry L Keyserling; Alexander Ploss; Charles M Rice; Walter A Orenstein; Mark J Mulligan; Rafi Ahmed
Journal:  J Immunol       Date:  2009-12-15       Impact factor: 5.422

9.  Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever.

Authors:  Juthathip Mongkolsapaya; Wanwisa Dejnirattisai; Xiao-ning Xu; Sirijitt Vasanawathana; Nattaya Tangthawornchaikul; Aroonrung Chairunsri; Siraporn Sawasdivorn; Thaneeya Duangchinda; Tao Dong; Sarah Rowland-Jones; Pa-thai Yenchitsomanus; Andrew McMichael; Prida Malasit; Gavin Screaton
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

10.  Development of an epitope conservancy analysis tool to facilitate the design of epitope-based diagnostics and vaccines.

Authors:  Huynh-Hoa Bui; John Sidney; Wei Li; Nicolas Fusseder; Alessandro Sette
Journal:  BMC Bioinformatics       Date:  2007-09-26       Impact factor: 3.169

View more
  83 in total

Review 1.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? There Is Only One True Winner.

Authors:  Scott B Halstead
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

Review 2.  Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Risks of Incomplete Immunity to Dengue Virus Revealed by Vaccination.

Authors:  Stephen S Whitehead; Kanta Subbarao
Journal:  Cold Spring Harb Perspect Biol       Date:  2018-06-01       Impact factor: 10.005

3.  Patterns of Cellular Immunity Associated with Experimental Infection with rDEN2Δ30 (Tonga/74) Support Its Suitability as a Human Dengue Virus Challenge Strain.

Authors:  Alba Grifoni; Michael Angelo; John Sidney; Sinu Paul; Bjoern Peters; Aruna D de Silva; Elizabeth Phillips; Simon Mallal; Sean A Diehl; Jason Botten; Jonathan Boyson; Beth D Kirkpatrick; Stephen S Whitehead; Anna P Durbin; Alessandro Sette; Daniela Weiskopf
Journal:  J Virol       Date:  2017-03-29       Impact factor: 5.103

4.  Human CD4+ T Cell Responses to an Attenuated Tetravalent Dengue Vaccine Parallel Those Induced by Natural Infection in Magnitude, HLA Restriction, and Antigen Specificity.

Authors:  Michael A Angelo; Alba Grifoni; Patrick H O'Rourke; John Sidney; Sinu Paul; Bjoern Peters; Aruna D de Silva; Elizabeth Phillips; Simon Mallal; Sean A Diehl; Beth D Kirkpatrick; Stephen S Whitehead; Anna P Durbin; Alessandro Sette; Daniela Weiskopf
Journal:  J Virol       Date:  2017-02-14       Impact factor: 5.103

Review 5.  Dengue: knowledge gaps, unmet needs, and research priorities.

Authors:  Leah C Katzelnick; Josefina Coloma; Eva Harris
Journal:  Lancet Infect Dis       Date:  2017-02-07       Impact factor: 25.071

Review 6.  Epitope prediction and identification- adaptive T cell responses in humans.

Authors:  John Sidney; Bjoern Peters; Alessandro Sette
Journal:  Semin Immunol       Date:  2020-10-31       Impact factor: 11.130

7.  T-cells producing multiple combinations of IFNγ, TNF and IL10 are associated with mild forms of dengue infection.

Authors:  Marcela Helena Gonçalves Pereira; Maria Marta Figueiredo; Camila Pereira Queiroz; Télcia Vasconcelos Barros Magalhães; Adriana Mafra; Lilian Martins Oliveira Diniz; Último Libânio da Costa; Kenneth J Gollob; Lis Ribeiro do Valle Antonelli; Helton da Costa Santiago
Journal:  Immunology       Date:  2020-04-06       Impact factor: 7.397

Review 8.  Vaccines licensed and in clinical trials for the prevention of dengue.

Authors:  J Torresi; G Ebert; M Pellegrini
Journal:  Hum Vaccin Immunother       Date:  2017-02-14       Impact factor: 3.452

Review 9.  Enhancing vaccine effectiveness with delivery technology.

Authors:  Marie Beitelshees; Yi Li; Blaine A Pfeifer
Journal:  Curr Opin Biotechnol       Date:  2016-03-06       Impact factor: 9.740

10.  Identification of Zika virus epitopes reveals immunodominant and protective roles for dengue virus cross-reactive CD8+ T cells.

Authors:  Jinsheng Wen; William Weihao Tang; Nicholas Sheets; Julia Ellison; Alessandro Sette; Kenneth Kim; Sujan Shresta
Journal:  Nat Microbiol       Date:  2017-03-13       Impact factor: 17.745

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.